MMED Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MiniMed Group Inc (MMED) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock is attractively valued, has strong analyst support, and operates in a high-growth industry. While there are no immediate trading signals or recent congress trading data, the company's growth potential and favorable risk/reward profile make it a compelling long-term investment.
The stock is currently trading at $14.28 in pre-market, with no significant trading trends from hedge funds or insiders. There is no recent stock trend data available to assess momentum.
Strong analyst support with multiple Buy and Overweight ratings from top firms like Goldman Sachs, Barclays, and Deutsche Bank. Price targets range from $16 to $67, indicating significant upside potential.
MiniMed operates in the high-growth diabetes technology market, valued at $18B globally and growing in the high-teens annually.
The company is a 'full-stack' diabetes technology provider with a differentiated product portfolio, including insulin pumps, glucose monitors, and integrated automated insulin delivery systems.
Piper Sandler's Neutral rating highlights concerns about MiniMed's competitive position in terms of form factor and ease of use, which could impact growth.
The company's EPS dropped to -0.1 in Q2 2026, reflecting challenges in profitability.
In Q2 2026, MiniMed reported a 10.26% YoY revenue increase to $752M and a 0% YoY change in net income, remaining at $0. Gross margin improved slightly to 57.05%, but EPS dropped by -9.09% YoY to -0.1, indicating profitability challenges.
Analysts are overwhelmingly positive, with 8 Buy/Overweight ratings and 1 Neutral rating. Price targets range from $16 to $67, with most analysts highlighting the company's attractive valuation, growth potential, and differentiated product portfolio.
